$1.17
2.50% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US88338N1072
Symbol
TXMD
Sector
Industry

TherapeuticsMD, Inc. Stock price

$1.17
-0.35 23.03% 1M
-0.05 4.10% 6M
+0.31 36.05% YTD
-0.81 40.91% 1Y
-64.33 98.21% 5Y
-399.33 99.71% 10Y
-0.03 2.50% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.03 2.50%
ISIN
US88338N1072
Symbol
TXMD
Sector
Industry

Key metrics

Market capitalization $13.54m
Enterprise Value $7.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 5.53
EV/Sales (TTM) EV/Sales 4.23
P/S ratio (TTM) P/S ratio 7.36
P/B ratio (TTM) P/B ratio 0.51
Revenue growth (TTM) Revenue growth 52.07%
Revenue (TTM) Revenue $1.84m
EBIT (operating result TTM) EBIT $-3.13m
Free Cash Flow (TTM) Free Cash Flow $1.41m
Cash position $5.75m
EPS (TTM) EPS $-0.19
Short interest 0.99%
Show more

Is TherapeuticsMD, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

TherapeuticsMD, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast TherapeuticsMD, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast TherapeuticsMD, Inc.:

Hold
100%

Financial data from TherapeuticsMD, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.84 1.84
52% 52%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.50 4.50
37% 37%
245%
- Research and Development Expense - -
-
-
-2.66 -2.66
55% 55%
-145%
- Depreciation and Amortization 0.47 0.47
54% 54%
26%
EBIT (Operating Income) EBIT -3.13 -3.13
55% 55%
-170%
Net Profit -2.10 -2.10
72% 72%
-114%

In millions USD.

Don't miss a Thing! We will send you all news about TherapeuticsMD, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TherapeuticsMD, Inc. Stock News

Neutral
Business Wire
about one month ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(636) thousand, or $(0.06) per basic and di...
Neutral
Business Wire
3 months ago
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per basic and diluted...

Company Profile

TherapeuticsMD, Inc. is a pharmaceutical company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Head office United States
CEO Mr. Walker
Employees 1
Founded 1907
Website www.therapeuticsmd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today